Endokrine Orbitopathie (Investigativer Periokulärer Zusatz)

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?

Not FDA-cleared for thyroid eye disease. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.

Welche Evidenz existiert?

Tier C (investigational). Anecdotal periocular reports only. Evidence-based first-line management is smoking cessation (critical), optimization of thyroid function, selenium supplementation in mild active disease, intravenous methylprednisolone for moderate-to-severe active disease, teprotumumab for active moderate-to-severe TED, orbital radiotherapy in select cases, and surgical orbital decompression for vision-threatening or quiescent severe disease.

Hauptrisiken

• Bleeding from each bite site for 6 to 10 hours after the leech detaches
• Iron-deficiency anemia from cumulative blood loss across multiple sessions
• Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
• Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
• Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
• Local pain, bruising, swelling, or itching for 1 to 3 days after each session
• Periocular bleeding, eyelid hematoma, or conjunctival bleeding (vision-threatening in active TED with proptosis)
• Worsening of corneal exposure if eyelid swelling temporarily increases
• Increased intraorbital pressure — theoretical risk to optic nerve in compressive TED

Wer dies nicht in Betracht ziehen sollte

• Patients with active vision-threatening TED (optic neuropathy, severe corneal exposure) — needs urgent IV steroids or surgery
• Patients still smoking — smoking cessation alone often improves TED course substantially
• Patients who have not had endocrine workup to confirm euthyroid status
• Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
• People with hemophilia or any other inherited bleeding disorder
• Patients with severe anemia (hemoglobin under 10 g/dL)
• People with an active infection at the planned application site

Was Sie Ihren Kliniker fragen sollten

• Have I had a full TED workup with an oculoplastic surgeon or endocrinologist?
• Is my thyroid hormone level optimized and have I stopped smoking?
• Am I a candidate for teprotumumab or IV methylprednisolone?
• What is the published periocular leech-therapy safety record?
• Who specifically will manage any bleeding or eyelid hematoma?
• How will optic nerve function be monitored during the course?

Wann dringende medizinische Versorgung suchen

• Bleeding from a bite site that soaks through more than one dressing per hour
• Bleeding that continues more than 24 hours after the leech detached
• Spreading redness, warmth, swelling, pus, or red streaks around any bite site
• Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
• Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
• Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
• Vision change of any kind — blurriness, color desaturation, dimness, or loss
• Severe eye pain, especially with eye movement
• Sudden inability to close the eye completely or new double vision